深圳市成年人血脂异常流行现况及影响因素分析

doi:10.12183/j.scjpm.2024.0314

摘要/Abstract

摘要： 目的了解深圳市成年人血脂异常流行现况及其影响因素,为制定深圳市血脂异常防控策略提供参考依据。方法采用多阶段分层随机抽样方法,于2021年4—12月对深圳市10个区≥18岁常住居民进行问卷调查、体格检查和实验室检测。采用多因素logistic回归分析血脂异常影响因素。结果本研究共纳入6 285名成年人,平均年龄（40.27±14.24）岁,男女性别比为0.99∶1。血脂异常2 300例,患病率为36.60%（标化患病率38.35%）。多因素分析结果显示,女性（OR=0.758）、体重过低（OR=0.446）是深圳市成年人血脂异常的保护因素;35~64岁年龄组（OR=1.832）、65~94岁年龄组（OR=1.811）、超重（OR=1.719）、肥胖（OR=2.289）、现在吸烟（OR=1.409）、高血压（OR=1.575）、糖尿病（OR=2.285）、高尿酸（OR=1.953）是深圳市成年人血脂异常的危险因素。结论深圳市成年人血脂异常患病率较高,需加强大龄男性、超重肥胖、吸烟及患有慢性疾病等高危人群血脂的监测和生活行为方式的干预,从而预防血脂异常的发生。

关键词: 成年人, 血脂异常, 流行特征, 影响因素

Abstract: Objective To understand the prevalence and influencing factors of dyslipidemia in adults in Shenzhen,and to provide reference for the prevention and control strategy of dyslipidemia in Shenzhen. Methods A multi‐stage stratified random sampling method was used to conduct questionnaire survey,physical examination,and laboratory testing among permanent residents aged ≥18 years in 10 districts of Shenzhen from April to December 2021. Multivariate logistic regression was used to analyze the influencing factors of dyslipidemia. Results A total of 6 285 adults were included,with a mean age of （40.27±14.24） years old,and male to female ratio was 0.99∶1,2 300 of the participants were dyslipidemia,the prevalence rate was 36.60% （the standardized prevalence rate was 38.35%）. The results of multivariate analysis showed that females （OR=0.758） and underweight （OR=0.446） were protective factors for dyslipidemia of adults in Shenzhen,and 35-64 years old （OR=1.832）,65-94 years old （OR=1.811）,overweight （OR=1.719）,obesity （OR=2.289）,current smoking （OR=1.409）,hypertension （OR=1.575）,diabetes （OR=2.285）,hyperuricemia （OR=1.953） were the risk factors. Conclusions The prevalence of dyslipidemia in adults in Shenzhen is high,and it is necessary to strengthen the monitoring of blood lipids and intervention of lifestyle in high‐risk groups such as older men,overweight and obese,smoking and chronic diseases,so as to prevent the occurrence of dyslipidemia.

Key words: Adult, Dyslipidemia, Epidemic characteristics, Influencing factor

中图分类号:

R195

谢尉, 赵志广, 吴肖冰, 谢凤珠, 尚庆刚, 武小艳, 吕德良. 深圳市成年人血脂异常流行现况及影响因素分析[J]. 华南预防医学, 2024, 50(4): 314-318.

XIE Wei, ZHAO Zhiguang, WU Xiaobing, XIE Fengzhu, SHANG Qinggang, WU Xiaoyan, LYU Deliang. Prevalence and influencing factors of dyslipidemia in adults in Shenzhen[J]. South China Journal of Preventive Medicine, 2024, 50(4): 314-318.

参考文献

[1] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志,2016,44(10):833-853.
[2] 赵文华,张坚,由悦,等. 中国18岁及以上人群血脂异常流行特点研究[J]. 中华预防医学杂志,2005,39(5):306-310.
[3] 国家卫生计生委疾病预防控制局. 中国居民营养与慢性病状况报告(2020年)[M]. 北京:人民卫生出版社,2021:73-77.
[4] Pirillo A,Casula M,Olmastroni E,et al.Global epidemiology of dyslipidaemias[J]. Nat Rev Cardiol,2021,18(10):689-700.
[5] Sun L,Clarke R,Bennett D,et al.Causal associations of blood lipids with risk of ischaemic stroke and intracerebral haemorrhage in Chinese adults[J]. Nat Med,2019,25(4):569-574.
[6] Moran A,Gu D,Zhao D,et al.Future cardiovascular disease in China:Markov model and risk factor scenario projections from the coronary heart disease policy model‐China[J]. Circ Cardiovasc Qual Outcomes,2010,3(3):243-252.
[7] 中国心血管病预防指南写作组,中华心血管病杂志编辑委员会. 中国心血管病预防指南(2017)[J]. 中华心血管病杂志,2018,46(1):10-25.
[8] 中华人民共和国卫生和计划生育委员会. WS/T 428—2013 成人体重判定[S]. 北京:中国标准出版社,2013.
[9] 中国高血压防治指南修订委员会,中国高血压联盟,中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.
[10] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志,2021,37(4):311-398.
[11] 中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13.
[12] 邵英,许晓君,许燕君,等. 广东省2018年≥18岁人群血脂异常流行特征及相关因素分析[J]. 中国慢性病预防与控制,2022,30(11):825-830.
[13] 吴洵,覃玉,苏健,等. 江苏省35~75岁居民血脂异常患病和治疗情况及影响因素分析[J]. 中国慢性病预防与控制,2020,28(4):291-295.
[14] 彭绩,余卫业. 深圳市慢性非传染性疾病流行病学调查研究(2018年)[M]. 北京:科学出版社,2021:171-184.
[15] Handelsman Y,Jellinger PS,Guerin CK,et al.Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary[J]. Endocr Pract,2020,26(10):1196-1224.
[16] Xi Y,Niu L,Cao N,et al.Prevalence of dyslipidemia and associated risk factors among adults aged ≥35 years in northern China:A cross‐sectional study[J]. BMC Public Health,2020,20(1):1068.
[17] Polyzos SA,Lambrinoudaki I,Goulis DG.Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease[J]. Hormones (Athens,Greece),2022,21(3):375-381.
[18] 张友琴,许秀娟,李祥微,等. 杭州市健康体检人群血脂异常及影响因素分析[J]. 华南预防医学,2022,48(3):286-289.
[19] Jeong W,Rezaei N.Association between dual smoking and dyslipidemia in South Korean adults[J]. PLoS One,2022,17(7):e270577.
[20] Nath D,Shivasekar M.Role of cigarette smoking on serum angiotensin‐converting enzyme and its association with inflammation and lipid peroxidation[J]. Cureus,2022,14(8):e27857.
[21] Zhu J,Zhang Y,Wu Y,et al.Obesity and dyslipidemia in Chinese adults:A cross‐sectional study in Shanghai,China[J]. Nutrients,2022,14(11):2321.
[22] Gao H,Wang H,Shan G,et al.Prevalence of dyslipidemia and associated risk factors among adult residents of Shenmu City,China[J]. PLoS One,2021,16(5):e250573.
[23] 游凯,肖春丽,赵红叶,等. 北京市顺义区成年居民血脂异常患病率、知晓率、治疗率和控制率现况及相关因素分析[J]. 华南预防医学,2021,47(8):1037-1041.
[24] Vekic J,Zeljkovic A,Stefanovic A,et al.Obesity and dyslipidemia[J]. Metabolism,2019,92:71-81.
[25] Dąbrowska E,Narkiewicz K.Hypertension and dyslipidemia:The two partners in endothelium‐related crime[J]. Curr Atheroscler Rep,2023,25(9):605-612.
[26] Athyros VG,Doumas M,Imprialos K P,et al.Diabetes and lipid metabolism[J]. Hormones (Athens),2018,17(1):61-67.
[27] Kuwabara M,Borghi C,Cicero AFG,et al.Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia:A five‐year cohort study in Japan[J]. Int J Cardiol,2018,261:183-188.